Lantheus Holdings, Inc. which can be found using ticker (LNTH) now have 11 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $175.00 and $125.00 and has a mean target at $144.55. Now with the previous closing price of $112.08 and the analysts are correct then we can expect a percentage increase in value of 29.0%. The day 50 moving average is $106.23 while the 200 day moving average is $81.83. The company has a market capitalization of 7.82B. Currently the stock stands at: $112.63 USD
The potential market cap would be $10,085,442,973 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 18.56, revenue per share of $20.91 and a 17.41% return on assets.
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company’s products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company’s license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
